Physician profile
William Burrow
NPI 1386658367
$1,878.58
in general payments reported to CMS, 2019-2025
17 companies · $99.12 in 2025
The $99.12 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $308 · 2021: $303 · 2022: $160 · 2023: $31.38 · 2024: $39.64 · 2025: $99.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $445.37 | 2019-2025 | Absorica Ld, Winlevi |
| Abbvie INC. | $348.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $271.30 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $213.68 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $189.04 | 2019-2024 | Dupixent |
| Leo Pharma INC. | $143.47 | 2019-2020 | |
| Lilly USA, LLC | $53.46 | 2019 | |
| Celgene Corporation | $39.96 | 2019 | |
| Janssen Biotech, INC. | $33.16 | 2020 | |
| Pfizer INC. | $32.77 | 2022-2025 | |
| Misonix INC | $27.00 | 2020-2021 | |
| Almirall LLC | $16.83 | 2019 | |
| Dermavant Sciences, INC. | $15.84 | 2022 | |
| Genentech USA, INC. | $15.46 | 2019 | |
| Ucb, INC. | $14.71 | 2025 | Bimzelx |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $11.08 | 2019 | |
| Biofrontera INC. | $7.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Burrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.